Nathalie Clement – VJRegenMed

Challenges in manufacturing viral vectors for the clinic

Simon Ng — Mon, 28 Feb 2022 17:56:23 +0000

Nathalie Clement, PhD, Unicorn Consultations, Gainesville, FL, describes challenges in the development and production of clinically effective viral vectors. Manufacturing larger doses on a bigger scale has been a barrier for companies, and difficulties in purification has led to issues in potency and safety. Finding a standard method for purifying viral vectors is especially difficult when there are numerous varieties of viral vectors including adeno-associated viruses and lentiviruses. Whilst the demand for viral vector gene therapies have increased in certain disease areas such as Duchenne muscular dystrophy, safety concerns possibly relating to impurities in the product must be addressed. This interview took place at Advanced Therapies Week 2022.

Key highlights at Advanced Therapies Week 2022

Simon Ng — Mon, 28 Feb 2022 17:56:18 +0000

Nathalie Clement, PhD, Unicorn Consultations, Gainesville, FL, provides some of her highlights during Advanced Therapies Week 2022. She highlights the opportunity to network with fellow attendees and obtain their perspectives on the latest developments the field, as well as plenary sessions that focus on the achievements of the previous year within the industry. This interview took place at Advanced Therapies Week 2022.

The past, present and future of AAV vectors

Simon Ng — Tue, 15 Feb 2022 12:24:08 +0000

Nathalie Clement, PhD, Unicorn Consultations, Gainesville, FL, provides an overview of her experiences working with adeno-associated viral (AAV) vectors, from its infancy of the field to the present day, where clinical trials are being conducted to assess AAV-based therapies. Dr Clement additionally highlights the growth of the AAV vector field and the increased demand for treatments, as well as the history of AAV vector research. This interview took place at Advanced Therapies Week 2022.

Innovations in viral vector development

Simon Ng — Tue, 15 Feb 2022 12:24:07 +0000

Nathalie Clement, PhD, Unicorn Consultations, Gainesville, FL, discusses strategies for safe and effective viral vector development. Whilst there are a variety of viral vectors including adeno-associated viral (AAV) vectors, there are common safety concerns. However, collaboration between stakeholders can drive innovation, especially in the case of developing an AAV-based COVID-19 vaccine, which required quick adaptation of existing technology for vaccine manufacturing. Dr Clement additionally describes research to improve vector yields as well as efforts to discover more efficient capsids. This interview took place at Advanced Therapies Week 2022.